Skip to main content
. 2015 Jun 4;4(8):561–568. doi: 10.1016/j.molmet.2015.05.005

Figure 1.

Figure 1

Effect of icv FGFR inhibitor on determinants of glucose tolerance in lean, fasted rats. icv FGFR inhibitor (FGFRi; PD173074; 150 μg) or vehicle DMSO (Veh) was administered via the 3rd cerebral ventricle in overnight fasted, lean rats (n = 16/group) and 30 min later (t = 0 min), animals underwent a frequently sampled intravenous glucose tolerance test (FSIGT). (A) Blood glucose levels (mg/dl), (B) glucose tolerance index, Kg (calculated as the slope of the natural logarithm of glucose from t = 4–25 min, expressed as percent change per min), (C) plasma insulin levels (ng/ml), (D) acute insulin response to glucose (AIRg; mUL−1min−1), (E) plasma lactate levels (mmol/l), (F) the lactate area under the curve (AUC) for pre- (−10 to 0 min) and post (1–20 min) iv glucose bolus, (G) plasma NEFA levels (mmol/l), and (H) NEFA ΔAUC (−10 to 60 min). Data are presented as the mean ± SEM; *p < 0.05 vs. icv Veh; #p < 0.05 vs. icv Veh, pre iv bolus.